ASH 2020 | Key updates in lymphoma from ASH 2020
Paolo Strati
• 17 Dec 2020
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares his highlights from ASH 2020, picking out a presentation of early data from the TRANSCEND-NHL-001 study (NCT02631044) investigating the safety and efficacy of lisocabtagene maraleucel for relapsed/refractory mantle cell lymphoma (MCL) and a Phase II study (NCT03618550) investigating a novel combination of pembrolizumab plus gemcitabine, vinorelbine and liposomal doxorubicin for relapsed/refractory Hodgkin lymphoma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
